Amid new government directives around diversity, equity, and inclusion programs in the US, our April issue explores the pivots and adjustments pharma and healthcare interests are making to maintain the progress of such efforts in advancing clinical research.
Related Posts
Enhancing Diversity Through Trial Design
ACT: What does the clinical research industry need to do better to recruit more underrepresented populations into their trials? Tirisham…
Parexel and Palantir Expand Collaboration to Leverage AI Capabilities in Clinical Trials
Image Credit: © lidiia – stock.adobe.com Parexel and Palantir Technologies have announced a new multi-year strategic partnership to leverage artificial…
Omvoh Achieves Long-Term Remission, Symptom Improvement for Ulcerative Colitis, Crohn Disease in Phase III Trials
Credit: antkevyv | stock.adobe.com A pair of multiyear Phase III trials show that Eli Lilly’s Omvoh (mirikizumab) produced stable, long-term…